[Indicators of oxidative stress and the effect of antioxidant treatment in patients with primary Parkinson disease].
OBJECTIVE
Parkinson's disease (PD) is characterized by a progressive, slow loss of dopaminergic neurones in the substance nigra. Although the cause of this neurone loss is unknown, at the present time many papers suggest oxidative stress (OS), secondary to dopaminergic metabolism, as an aetiopathogenic factor of PD. Therefore study of the part played by OS in this would permit the use of antioxidants (AO) as another possibility for treatment of the disease. It would also be a major step forward in the search for possible biological markers.


METHODS
A study using spectrophotometric techniques was made of the serum levels of four biochemical indicators: catalase (CAT), malonyl aldehyde (MDA), phospholipase A2 (PLA2) and Vitamin C (VITC) in controls and in patients with PD. We found the average value for each of the variables studied in controls and in patients, taking AO treatment into account.


RESULTS
The effect of clinical variables on serum levels of CAT, MDA, PLA2 and VITC was analyzed. It was seen that only the clinical state of Hoen and Yahr was related to the biochemical indicators. The CAT activity and VITC concentration showed statistically significant differences between patients (independently of their AO treatment) and controls. The CAT activity was significantly less in those treated with AO. The patients with PD did not all have the same degree of OS. The effect of AO treatment on plasma markers showed changes only in one subgroup of Parkinson patients.


CONCLUSIONS
Our study suggests that AO treatment in this condition should be tailored to the individual patient according to the degree of OS present.
González-Fraguela
M E
ME
Departamento de Neurobioquímica, CIBIOMED, Ciudad de La Habana, Cuba. cineuro@neuro.sld.cu
Céspedes
E M
EM
Arencibia
R
R
Broche
F
F
Gómez
A A
AA
Castellano
O
O
García
J C
JC
D000975:Antioxidants / Q000494:pharmacology* / Q000627:therapeutic use*; D001205:Ascorbic Acid / Q000097:blood / Q000494:pharmacology* / Q000627:therapeutic use*; D015415:Biomarkers; D002374:Catalase / Q000097:blood; D018450:Disease Progression; D006801:Humans; D008315:Malondialdehyde / Q000097:blood; D008996:Monoamine Oxidase Inhibitors / Q000494:pharmacology* / Q000627:therapeutic use*; D018384:Oxidative Stress / Q000187:drug effects*; D010300:Parkinson Disease / Q000188:drug therapy* / Q000201:enzymology; D010741:Phospholipases A / Q000097:blood / Q000378:metabolism; D054467:Phospholipases A2; D017382:Reactive Oxygen Species / Q000378:metabolism; D013053:Spectrophotometry / Q000379:methods; D014810:Vitamin E / Q000494:pharmacology* / Q000627:therapeutic use*
D000975:Antioxidants; D015415:Biomarkers; D008996:Monoamine Oxidase Inhibitors; D017382:Reactive Oxygen Species; D014810:Vitamin E; D008315:Malondialdehyde; D002374:Catalase; D010741:Phospholipases A; D054467:Phospholipases A2; D001205:Ascorbic Acid
Indicadores de estrés oxidativo y efecto del tratamiento antioxidante en pacientes con enfermedad de Parkinson primaria.